Anti-Fibrotic Effects Of Nintedanib (bibf 1120) In Primary Human Lung Fibroblasts Derived From Patients With Idiopathic Pulmonary Fibrosis And From Non-Fibrotic Controls

被引：0
作者：
Hostettler, K. E. [1 ]
Papakonstantinou, E. [2 ]
Klagas, J. [2 ]
Karakiulakis, G. [2 ]
Zhong, J. [1 ]
Tamm, M. [1 ]
Lardinois, D. [1 ]
Roth, M. [1 ]
机构：
[1] Univ Basel Hosp, Basel, Switzerland
[2] Univ Thessaloniki, Thessaloniki, Greece
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3374
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Dermal Fibroblasts from Patients with Lupus Nephritis Express an Anti-Fibrotic Transcriptome
    Clancy, Robert M.
    Der, Evan
    Akat, Kemal
    Broder, Anna R.
    Belmont, H. Michael
    Izmirly, Peter M.
    Goilav, Beatrice
    Tuschl, Thomas
    Putterman, Chaim
    Buyon, Jill P.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [42] WEIGHT LOSS HAS A SIGNIFICANT IMPACT ON ANTI-FIBROTIC DRUG TOLERANCE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Moon, R. D. C.
    Barker, E.
    Agnew, S.
    Sutcliffe, J.
    Kwok, A.
    Spencer, L. G.
    THORAX, 2017, 72 : A250 - A250
  • [43] Anti-Fibrotic Role Of Inhaled Interferon-γ Detected By Proteomic Studies In Patients With Idiopathic Pulmonary Fibrosis
    Hasaneen, N. A.
    Haley, J.
    Foda, H. D.
    Condos, R.
    Smaldone, G. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [44] Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
    Takumi Yoshikawa
    Mitsuo Otsuka
    Hirofumi Chiba
    Kimiyuki Ikeda
    Yuki Mori
    Yasuaki Umeda
    Hirotaka Nishikiori
    Koji Kuronuma
    Hiroki Takahashi
    BMC Pulmonary Medicine, 20
  • [45] Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis
    Kurumiya, Eon
    Iwata, Mayuu
    Kasuya, Yoshitoshi
    Tatsumi, Koichiro
    Honda, Takuya
    Murayama, Toshihiko
    Nakamura, Hiroyuki
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 966
  • [46] Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery
    Bongiolatti, Stefano
    Salvicchi, Alberto
    Rosi, Elisabetta
    Bargagli, Elena
    Mugnaini, Giovanni
    Gonfiotti, Alessandro
    Lavorini, Federico
    Spagnolo, Paolo
    Dell'Amore, Andrea
    Rea, Federico
    Voltolini, Luca
    LIFE-BASEL, 2024, 14 (11):
  • [47] Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
    M. Molina-Molina
    C. Machahua-Huamani
    V. Vicens-Zygmunt
    R. Llatjós
    I. Escobar
    E. Sala-Llinas
    P. Luburich-Hernaiz
    J. Dorca
    A. Montes-Worboys
    BMC Pulmonary Medicine, 18
  • [48] Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients
    Zanotti, Simona
    Bragato, Cinzia
    Zucchella, Andrea
    Maggi, Lorenzo
    Mantegazza, Renato
    Morandi, Lucia
    Mora, Marina
    LIFE SCIENCES, 2016, 145 : 127 - 136
  • [49] Effects of Anti-Fibrotic Standard-of-Care and Senolytic Drugs on Senescent Human Lung Fibroblasts
    Garcia, S.
    Hohmann, M.
    Espindola, M. S.
    Hogaboam, C. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [50] Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
    Molina-Molina, M.
    Machahua-Huamani, C.
    Vicens-Zygmunt, V.
    Llatjos, R.
    Escobar, I.
    Sala-Llinas, E.
    Luburich-Hernaiz, P.
    Dorca, J.
    Montes-Worboys, A.
    BMC PULMONARY MEDICINE, 2018, 18
12345